Allogene Therapeutics
ALLO
conference date: November 5, 2026 @ 2:00 PM PT
for quarter ending: September 30, 2026 (third quarter, Q3 2026)

Forward-looking
statements
Overview: Pipeline continues to develop, more data on November 9.
Basic data (GAAP):
Revenue was $0 million, down sequentially from $4.6 and up from $0 year-earlier.
GAAP Net Income was negative $50.4 million, down sequentially from negative $42.7 million, and down from negative $41.4 million year-earlier.
GAAP EPS was negative $0.15, down sequentially from negative $0.13, and down from negative $0.19 year-earlier.
Guidance:
Cash runway into 2029. 2026 operating expernse $225 million GAAP, $165 million non-GAAP.
Conference Highlights:
Zachary Roberts, CEO said "CAR T has transformed what's possible in medicine, but toxicity and treatment complexity have kept its full potential out of reach for too many patients. We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient’s disease and closer to where they receive care. At the same time, our ALLO-329 data set to be released next week will begin to address an equally important question in autoimmune disease: whether we can deliver meaningful clinical benefit with less reliance on chemotherapy-based conditioning. Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients."
Cema-Cel (ALLO-501 or cemacabtagene ansegedleucel) for large B cell lymphona (LBCL) pivotal Phase 2 study (Alpha3) enrollment completion expected year-end 2027, data updates in 2027, final data in 2028. Futility analysis was presented in April 2026: MRD negativity at 45 days was 58.3% with cema-cel, v. 16.7% in control arm. Well tolerated. Cema-Cel is an allogeneic cell therapy. EFS primary endpoint. Believes the market opportunity has expanded to more than $9.5 billion. Could make a BLA submission in 2027 if interim data positive. In Q3 2026 the FDA granted RMAT (Regenerative Medicine Advanced Therapy) and fast track designations. Preparing for commercialization.
ALLO-329 for autoimmune disease started Phase 1 trial for rheumatology indications began in Q2 2025. Brisk enrollment across cohorts and dose levels. Initial data expected November 9, 2026. Beginning to see signs of clinical activity. Resolution is a basket trial across several autoimmune conditions including lupus, systemic sclerosis, and idiopathic inflammatory myopathies. Targets both CD19 and CD70. Has Dagger technology to eliminate lymphodepletion. Believes differentiated from competitors.
ALLO-316 Phase 1 results for renal cell carcinoma is being discussed at two presentations at SITC. On November 5 renal cell carcinoma was discussed including evidence of durable responses. On November 6 a presentation on Allogene's broader CAR T vision will be made. This includes the Dagger technology and pairing a DLL3 CAR with a CD70 CAR.
Total operating expenses (GAAP) were $55 million, consisting of: R&D $42 million; G&A $13 million; impairment $0 million. Loss from operations was $55 million. Other income net $4 million. Income tax $0 million.
Cash and equivalents ended at $389 million, down sequentially from $424 million.
Q&A selective summary:
The conference was not available the morning of 11/6, the link does not work, I may come back to it.
OpenIcon
Analyst Conference Summaries Main Page
|